Cln as a β2-AR agonist via the upregulation of Cx43 expression can increase the permeability of GCV-TP to GBM cells and, through the enhancement of the bystander effect between the cells, could increase the efficacy of gene therapy in these tumors. The gene discussed is ADRB2; the disease is glioblastoma.